News

Video

Treatment for Recurrent Endometrial Cancer: Chemotherapy or Lenvatinib + Pembrolizumab

Learn about the factors that influence the choice between chemotherapy re-challenge and the combination of lenvatinib and pembrolizumab for endometrial cancer treatment in the context of clinical data.

Related Videos
Matthew Powell, MD
Alberto Montero, MD, MBA, CPHQ
Kathleen N. Moore, MD, MS
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine